1. Hims & Hers Health is considered undervalued with a forecast P/S ratio of 3.5, despite 88% YoY revenue growth and European expansion via ZAVA; 2. Technical analysis indicates strong support at $41, suggesting a favorable buying opportunity, though high short interest makes a short squeeze unlikely; 3. Risks include legal uncertainties and potential declines in GLP-1 drug sales, but the author remains bullish and continues accumulating shares.